Suscripción a Biblioteca: Guest
Critical Reviews™ in Neurobiology

Publicado 3 números por año

ISSN Imprimir: 0892-0915

ISSN En Línea: 2375-0014

SJR: 0.121
Más
Comprar $35.00(open in a new tab) Comprobar suscripción Descargar registro MARC(open in a new tab) Obtener permisos(open in a new tab)

Adenosine A2A Receptor Antagonism and Neuroprotection: Mechanisms, Lights, and Shadows

Volumen 16, Edición 1&2, 2004, pp. 99-106
DOI: 10.1615/CritRevNeurobiol.v16.i12.110
Get accessGet access
Patrizia Popoli
Department of Drug Research and Evaluation, Istituto Superiore di Sanita, Roma, Italy
Luisa Minghetti
Department of Cell Biology and Neuroscience, Istituto Superiore di Sanita, Roma, Italy
Maria Teresa Tebano
Department of Drug Research and Evaluation, Istituto Superiore di Sanita, Roma, Italy
Annita Pintor
Department of Drug Research and Evaluation, Istituto Superiore di Sanita, Roma, Italy
Maria Rosaria Domenici
Department of Drug Research and Evaluation, Istituto Superiore di Sanita, Roma, Italy
Marino Massotti
Department of Drug Research and Evaluation, Istituto Superiore di Sanita, Roma, Italy

SINOPSIS

Adenosine A2A receptor antagonists are regarded as potential neuroprotective drugs, although the mechanisms underlying their effects remain to be elucidated. In this review, quinolinic acid (QA)-induced striatal toxicity was used as a tool to investigate the mechanisms of the neuroprotective effects of A2A receptor antagonists. After having examined the effects of selective A2A receptor antagonists toward different mechanisms of QA toxicity, we conclude that (1) the effect elicited by A2A receptor blockade on QA-induced glutamate outflow may be one of the mechanisms of the neuroprotective activity of A2A receptor antagonists; (2) A2A receptor antagonists have a potentially worsening influence on QA-dependent NMDA receptor activation; and (3) the ability of A2A receptor antagonists to prevent QA-induced lipid peroxidation does not correlate with the neuroprotective effects.
These results suggest that A2A receptor antagonists may have either potentially beneficial or detrimental influence in models of neurodegeneration that are mainly due to increased glutamate levels or enhanced sensitivity of NMDA receptors, respectively.

CITADO POR

  1. Minghetti Luisa, Greco Anita, Potenza Rosa Luisa, Pezzola Antonella, Blum David, Bantubungi Kadiombo, Popoli Patrizia, Effects of the Adenosine A2A Receptor Antagonist SCH 58621 on Cyclooxygenase-2 Expression, Glial Activation, and Brain-Derived Neurotrophic Factor Availability in a Rat Model of Striatal Neurodegeneration, Journal of Neuropathology and Experimental Neurology, 66, 5, 2007. Crossref

  2. Booth Lindsea C, Tummers Leonie, Jensen Ellen C, Barrett Carolyn J, Malpas Simon C, Gunn Alistair J, Bennet Laura, DIFFERENTIAL EFFECTS OF THE ADENOSINE A1RECEPTOR AGONIST ADENOSINE AMINE CONGENER ON RENAL, FEMORAL AND CAROTID VASCULAR CONDUCTANCE IN PRETERM FETAL SHEEP, Clinical and Experimental Pharmacology and Physiology, 35, 11, 2008. Crossref

  3. Tebano Maria Teresa, Martire Alberto, Chiodi Valentina, Pepponi Rita, Ferrante Antonella, Domenici Maria Rosaria, Frank Claudio, Chen Jiang-Fan, Ledent Catherine, Popoli Patrizia, Adenosine A2Areceptors enable the synaptic effects of cannabinoid CB1receptors in the rodent striatum, Journal of Neurochemistry, 110, 6, 2009. Crossref

  4. Fuxe Kjell, Marcellino Daniel, Genedani Susanna, Agnati Luigi, Adenosine A2Areceptors, dopamine D2receptors and their interactions in Parkinson's disease, Movement Disorders, 22, 14, 2007. Crossref

  5. Domenici M.R., Scattoni M.L., Martire A., Lastoria G., Potenza R.L., Borioni A., Venerosi A., Calamandrei G., Popoli P., Behavioral and electrophysiological effects of the adenosine A2A receptor antagonist SCH 58261 in R6/2 Huntington’s disease mice, Neurobiology of Disease, 28, 2, 2007. Crossref

  6. Galluzzo Mariangela, Pintor Anita, Pèzzola Antonella, Grieco Rosa, Borsini Franco, Popoli Patrizia, Behavioural and neurochemical characterization of the adenosine A2A receptor antagonist ST1535, European Journal of Pharmacology, 579, 1-3, 2008. Crossref

  7. Martire Alberto, Calamandrei Gemma, Felici Fabio, Scattoni Maria Luisa, Lastoria Giusi, Domenici Maria Rosaria, Tebano Maria Teresa, Popoli Patrizia, Opposite effects of the A2A receptor agonist CGS21680 in the striatum of Huntington's disease versus wild-type mice, Neuroscience Letters, 417, 1, 2007. Crossref

  8. Chiodi Valentina, Mallozzi Cinzia, Ferrante Antonella, Chen Jiang F, Lombroso Paul J, Di Stasi Anna Maria Michela, Popoli Patrizia, Domenici Maria Rosaria, Cocaine-Induced Changes of Synaptic Transmission in the Striatum are Modulated by Adenosine A2A Receptors and Involve the Tyrosine Phosphatase STEP, Neuropsychopharmacology, 39, 3, 2014. Crossref

  9. Seidl Stacey E., Santiago Jose A., Bilyk Hope, Potashkin Judith A., The emerging role of nutrition in Parkinson's disease, Frontiers in Aging Neuroscience, 6, 2014. Crossref

  10. Cunha Rodrigo A., How does adenosine control neuronal dysfunction and neurodegeneration?, Journal of Neurochemistry, 139, 6, 2016. Crossref

  11. Pinna Annalisa, Simola Nicola, Frau Lucia, Morelli Micaela, Symptomatic and Neuroprotective Effects of A2A Receptor Antagonists in Parkinson’s Disease, in Adenosine, 2013. Crossref

  12. Sebastião Ana M., Ribeiro Joaquim A., Adenosine Receptors and the Central Nervous System, in Adenosine Receptors in Health and Disease, 193, 2009. Crossref

  13. Armida Monica, Matteucci Alessandra, Pèzzola Antonella, Baqi Younis, Müller Christa E., Popoli Patrizia, Potenza Rosa Luisa, Modulating P1 Adenosine Receptors in Disease Progression of SOD1G93A Mutant Mice, Neurochemical Research, 44, 5, 2019. Crossref

  14. Tebano M. T., Martire A., Pepponi R., Domenici M. R., Popoli P., Is the functional interaction between adenosine A2A receptors and metabotropic glutamate 5 receptors a general mechanism in the brain? Differences and similarities between the striatum and the hippocampus, Purinergic Signalling, 2, 4, 2006. Crossref

1138 Vistas de artículos 22 Descargas de artículos Métrica
1138 PUNTOS DE VISTA 22 DESCARGAS 14 Crossref CITAS Google
Scholar CITAS

Artículos con contenido similar:

Behavioral Effects of Cannabinoid Agents in Animals Critical Reviews™ in Neurobiology, Vol.13, 1999, issue 3
Marie-Helene Thiebot, Frederique Chaperon
Evaluation of Adverse Cardiac Effects Induced by Arsenic Trioxide, a Potent Anti-APL Drug Journal of Environmental Pathology, Toxicology and Oncology, Vol.28, 2009, issue 3
Richa Singh, K. G. Raghu, Sharad Sharma, A. Prathapan, Govind Kumar Yadav, Smrati Bhadauria
Adaptations in Adenosine Signaling in Drug Dependence: Therapeutic Implications Critical Reviews™ in Neurobiology, Vol.15, 2003, issue 3&4
Macdonald J. Christie, Stephen P. Hack
Impairment of GABAergic Transmission in Depression: New Insights from Neuroimaging Studies Critical Reviews™ in Neurobiology, Vol.14, 2000, issue 1
John H. Krystal, Graeme F. Mason, Gerard Sanacora
A Key Glycolytic Enzyme Plays a Dual Role in GABAergic Neurotransmission and in Human Epilepsy Critical Reviews™ in Neurobiology, Vol.18, 2006, issue 1-2
Rene Pumain, Jacques Laschet

Último edicion

Dopaminergic Modulation of the Neuron Activity in the Cerebral Cortex of the Wakeful Animal Victor M. Storozhuk
Portal Digitalde Biblioteca Digital eLibros Revistas Referencias y Libros de Ponencias Colecciones Precios y Políticas de Suscripcione Begell House Contáctenos Language English 中文 Русский Português German French Spain